In a review of recent notable events, CF Industries Holdings (CF) has emerged as a bio-tech company to watch. The firm has shown significant growth, marked by strong earnings and completed share buybacks. It was not all rosy, as the company's stock underperformed on some days compared to its competitors. It's also worth mentioning the sales of shares by insiders, namely Susan Menzel, CF Industries EVP, who sold stock worth $311,858.
CF Industries has also been in the news regarding its shift in investment narrative caused by mixed analyst signals, though Scotiabank maintained their hold rating on CF Industries Holdings. They also reported full year 2025 net earnings of $1.46 billion, and adjusted EBITDA of $2.89 billion which prompted a price target raise by UBS. The bio-tech firm continues its low carbon push, battling against outages and valuation outlook. They are also gearing up participate in an upcoming investor conference.
Various other noteworthy events include the issuance of a positive forecast for CF Industries by BNP Paribas Exane, Q1 earnings forecast by Scotiabank and price target lifts by RBC.
Cf Industries Holding CF News Analytics from Sun, 21 Sep 2025 07:00:00 GMT to Sat, 28 Feb 2026 22:00:17 GMT - Rating 7 - Innovation 4 - Information 8 - Rumor 6
